Peptide pain evidence index
Bottom line: “Peptide” is a molecule category, not a guarantee. The evidence runs from an FDA-approved pain medicine to products with no established human benefit.
| Intervention | What was studied | Human evidence | U.S. status |
|---|---|---|---|
| Ziconotide | Severe chronic pain | Controlled trials; established specialist use | FDA-approved for a narrow indication |
| Semaglutide | Knee osteoarthritis pain in people with obesity | One large, high-quality randomized trial | Approved for other indications, not specifically arthritis pain |
| Collagen peptides | Knee osteoarthritis symptoms | Multiple randomized trials; results favorable but heterogeneous | Dietary supplements, not FDA-approved pain drugs |
| Cibinetide / ARA-290 | Small-fiber neuropathy | Small early trials; clinical benefit not established | Investigational; not FDA-approved |
| BPC-157 | Pain and injury recovery claims | Very limited human evidence; no reliable proof of benefit | Not FDA-approved |
| TB-500 | Healing and tissue-repair claims | No established human clinical evidence | Not FDA-approved |
How to read the index
Established means a treatment has controlled human evidence and a defined medical use. Promising means a signal exists but important questions remain. Not established means testimonials, animal experiments, or a trial registration are doing more work than completed human outcomes.
Approval is not the same as usefulness for every patient. Likewise, lack of approval does not prove a molecule can never work. It means the necessary case has not been made.
Download the underlying data
Download as CSV or view the JSON dataset. Each record includes scope, status, source, review date, and the central evidence limitation.
Last reviewed August 11, 2026. To report a correction or new study, contact the editorial desk.